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Multi-state models for the analysis of
time-to-treatment modification among HIV
patients under highly active antiretroviral
therapy in Southwest Ethiopia
Belay Birlie1* , Roel Braekers2, Tadesse Awoke3, Adetayo Kasim4 and Ziv Shkedy2
Abstract
Background: Highly active antiretroviral therapy (HAART) has shown a dramatic change in controlling the burden of
HIV/AIDS. However, the new challenge of HAART is to allow long-term sustainability. Toxicities, comorbidity,
pregnancy, and treatment failure, among others, would result in frequent initial HAART regimen change. The aim of
this study was to evaluate the durability of first line antiretroviral therapy and to assess the causes of initial highly
active antiretroviral therapeutic regimen changes among patients on HAART.
Methods: A Hospital based retrospective study was conducted from January 2007 to August 2013 at Jimma
University Hospital, Southwest Ethiopia. Data on the prescribed ARV along with start date, switching date, and reason
for change was collected. The primary outcome was defined as the time-to-treatment change. We adopted a
multi-state survival modeling approach assuming each treatment regimen as state. We estimate the transition
probability of patients to move from one regimen to another.
Result: A total of 1284 ART naive patients were included in the study. Almost half of the patients (41.2%) changed
their treatment during follow up for various reasons; 442 (34.4%) changed once and 86 (6.69%) changed more than
once. Toxicity was the most common reason for treatment changes accounting for 48.94% of the changes, followed
by comorbidity (New TB) 14.31%. The HAART combinations that were robust to treatment changes were tenofovir
(TDF) + lamivudine (3TC)+ efavirenz (EFV), tenofovir + lamivudine (3TC) + nevirapine (NVP) and zidovudine (AZT) +
lamivudine (3TC) + nevirapine (NVP) with 3.6%, 4.5% and 11% treatment changes, respectively.
Conclusion: Moving away from drugs with poor safety profiles, such as stavudine(d4T), could reduce modification
rates and this would improve regimen tolerability, while preserving future treatment options.
Keywords: HIV/AIDS, Highly active antiretroviral therapy, Treatment modification, Survial analysis, Multistate models
Background
The implementation of HAART at a large scale has shown
a dramatic change in controlling the burden of HIV/AIDS.
Various studies from developed as well as developing
countries have reported an improvement in CD4 cell
counts following ART initiation [1–6] and decreases in
mortality [7].
*Correspondence: belaya.birlie@gmail.com
1Department of Statistics, Jimma University, Jimma, Ethiopia
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Currently, Ethiopia and most resource-limited coun-
tries have adopted non-nucleoside reverse transcrip-
tase inhibitors (NNRTIs) based therapy. They use either
NVP or EFV plus two nucleoside reverse transcriptase
inhibitors (NRTI) as a first line therapy for adults and
adolescents. This combination has been shown to be effi-
cacious, are generally less expensive, and have generic for-
mulations [7]. However, the new challenge of HAART is to
allow long-term durability. Many patients will be forced to
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modify or switch their treatment regimens for various rea-
sons, including poor drug tolerance, drug toxicities, drug-
to-drug interactions, pregnancy and treatment failure
[8–10].
Studies from developed and developing countries have
shown that a substantial number of patients (up to 69%)
may modify their regimen overtime, where 25% - 44%
of them modify their initial treatment within the first
years of treatment [8–14]. Drug related toxicity was
the most common reason for treatment modification
[8, 9, 11, 13, 15–18] and this can be an important bar-
rier to adherence and potentially lead to treatment failure
[19]. The majority of these studies found that patients
that receive d4T as a part of their treatment were at
increased risk of treatment modification due to toxicity
[13, 15–18], which raises questions about the continued
role of d4T in first-line treatment. The WHO had revised
its guidelines on the use of antiretroviral drugs several
times. Recently, WHO recommends to move away from
d4T giving preference to the use of TDF and AZT in
standard first-line therapy when possible [20, 21]. Due
to cost and management of toxicity, however, the transi-
tion from d4T to TDF has been slow in resource-limited
settings [20, 21].
The high rate of HAART switching emphasizes the
complexity of managing these therapies. Given the lim-
ited number of second-line treatment options available
in resource-limited settings, maximizing regimen durabil-
ity by minimizing the rate of treatment modification and
rates of treatment failure amongst those on first-line reg-
imens is vital to extend first-line treatment options and
prevent premature initiation of second-line therapy. In
order to achieve this goal, key reasons for changes in ART
regimens should be studied and durable regimens should
be identified for recommendations. Moreover, evaluating
the influence of initial ART regimens on the likelihood
of treatment modification has a vital role in determining
what treatment to initiate and what treatment to preserve.
Although relevant data on patients’ long-term experience
on ART from resource limited settings are less commonly
available, some investigators have described the reasons
for modification of HAART and compared durability of
individual ARV’s using routine clinical programme data
[15–18, 22–27]. However, the majority of these studies
have had short follow-up times and consider only first
time regimen switching or first time single drug sub-
stitution with no distinction made between NNRTI and
NRTI substitutions.
Therefore, this study aims to compare the durabil-
ity of first-line ART regimens and investigate reasons
for treatment modification in patients under HAART in
Jimma university specialized hospital. For this purpose,
we adopted a multi-state survival modeling approach
assuming each treatment regimen as state. We estimate
the transition probability of patients to move from one
regimen to another in general as well as due to a specific
event that triggers the move. The proposed model allows
modelling of both the occurrence of different event types
(such as, single drug substitution or regimen switch) and
the occurrence of subsequent events, the latter potentially
of different types.
Methods
Data
Description of the cohort
The data used for this study were obtained from Jimma
University Specialized Hospital HIV/AIDS clinic, located
352 Km Southwest of Addis Ababa, Ethiopia. The Hospi-
tal gives VCT, PMTCT and free ART service for people
living in Jimma Town and Southwest Ethiopia. Patients
begin ART after they have been checked for medical eli-
gibility and are counseled for adherence for ART. Patients
presenting withWHO stage 4 disease and/or a CD4 count
lower than 200 were eligible to start ART. Those who
started ART, have a regular follow-up for drug adverse
effects, management of opportunistic infection, TB screen
and counseling related to family planning. In addition,
CD4 count is measured at each visit. Viral load measure-
ment is not available. Adverse event monitoring is con-
ducted by clinicians during medical visits in accordance
with national guidelines.
Decisions on which treatment regimen to start or sub-
stitute are made by the clinician in consultation with the
patient. During the study period, the standard first-line
regimens to be initiated were d4T + 3TC + NVP (1), d4T
+ 3TC + EFV (2), AZT + 3TC + NVP (3), AZT + 3TC
+ EFV (4), TDF + 3TC + EFV (5), and TDF + 3TC +
NVP (6). If a patient suffered from side effects/toxicities
related to the NRTI’s (d4T, AZT or TDF), and was not in
need of second-line therapy for virologic failure, the rec-
ommendation was to substitute d4T with either AZT or
TDF, to substitute AZT either with d4T or TDF, and to
substitute TDF with either d4T or AZT. Similarly, patients
initiated on the NNRTI EFV could substitute with NVP,
while those on NVP could substitute with EFV. In addi-
tion, upon the recommendation of WHO, in Oct 2012
the hospital started to phase out d4T backbone by replac-
ing either AZT or TDF for patients who were on d4T
based regimen.
All data, including demographic, clinical conditions,
laboratory test results and medications are recorded and
entered in to the database by a data entry clerk at the
clinic. In addition, data on prescribed ARV along with
start and stop dates of the drug and reasons for discontin-
uation are documented. Use of Jimma University Hospital
HIV/AIDS clinic data and analysis of de-identified data
was approved by the Human Research Ethics Committee
of Jimma University.
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Study population
All ART naive patients, aged 18 years or older and who
initiated a standard, public-sector, first-line ART regi-
men at the clinic between between January 1, 2007 and
December 31, 2011 were eligible for this analysis. The data
was closed for analysis at the end of August, 2013.
Outcome
The primary outcome was defined as the time-to-
treatment change (treatment modification or regimen
switching). For the purpose of this study, treatment
change is defined as changing at least one ARV in the regi-
men without initiating a second-line therapy. ARV dosage
adjustments were not considered as treatment change.
Time zero was defined as the day of ART initiation and
each recurrent treatment change time was measured from
the beginning of the patient’s ART initiation in months.
Person-time of the study subject ended at the earliest
of initiation on second-line therapy, lost to follow up,
death, transfer or closure of the data set for analysis
(August 25, 2013).
Multi-state survival model
Model formulation
Possible transition between treatment combinations are
presented in Fig. 1 which illustrates the treatment his-
tory of patients under ART. From here onward we use
the term state to denote a specific treatment combination.
The model has 6 transient states (which represents 6 first-
line treatment combinations): d4T + 3TC + NVP (1), d4T
+ 3TC + EFV (2), AZT + 3TC + NVP (3), AZT + 3TC +
EFV (4), TDF + 3TC + EFV (5), and TDF + 3TC + NVP
(6). The model assumes that every patient can switch to
all the regimen at one point or other. However, a patient
can only switch to one regime at a time. For example, a
patient who started treatment with d4T + 3TC + NVP
State 1) is at risk of making one of the following transitions
at a particular time; 1 → 2, 1 → 3, 1 → 4, 1 → 5 and
1 → 6. If the patients made the transition 1 → 2 or 1 →
3, the subject has undergone a single drug-substitution
(treatment modification). Transition 1 → 2 implies that
the patient has substituted their NNRTI’s NVP by EFV
without changing their NRTI treatment (d4T). However,
transition 1 → 3 implies that the patient has substituted
their NRTI’s d4T by AZT without changing their NNRTI
treatment. Transitions 1 → 4 or 1 → 5, imply regi-
men switching, substituting both NNRTI and NRTI at the
same time. After making one of these possible transitions
patients will be at risk of making further transition.
Let (Xt)t>0 be a multi-state process with a state space
{1, 2, . . . , 6}. The stochastic process (Xt)t>0 is defined
as Xt = , if the process is in state  at time t (in
months). As mentioned above, for the case study pre-
sented in this paper, there are 6 possible first lines reg-
imens which implies that the initial state of the patient
X0 ∈ {1, 2, . . . , 6}.
Our main interest is to model the transition from th
regimen (state ) to jth regimen (state j) at time t. A tran-
sition will be simply denoted by j. The distribution of
this multi-state process is characterized by the transi-
tion intensities, or hazard rate, aj(t), which expresses the
instantaneous risk of a transition from state  into state j
at time t, that is
aj(t) = lim
t→0
P(X(t+t) = j|Xt = , Ft− )
t , , j ∈ {1, 2, ..., 6},  = j.
(1)
Here, Ft− represents process history prior to time t. In
our application, time t represents time since ART ini-
tiation. The cumulative transition hazards is defined as
Aj(t) =
∫ t
0 aj(u)du,u ≤ t, where Aj(t) = 0 if a
direct transition between state  and j is impossible. These
intensities can be gathered in to a 6 × 6 matrix A(t)
with diagonal elements A(t) = −∑6j=1,j = Aj(t), , j =
Fig. 1 A Six-state multi state model for treatment change. Note that 3TC was omitted because it was present in all the regimens. The transition
intensities matrix is presented in Additional file 1: Section S2
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{1, 2, . . . , 6}. Note that individuals who have no transition
should remain on their initial regimen (starting state) after
ART initiation .
A central issue related to ARTmanagement is the ability
to estimate the probability of the future treatment com-
bination of the patient (i.e. the patient state) given all
the information available until the present moment. For
example, given a patient who substituted his NRTI’s d4T
by AZT without changing his NNRTI after 6 months and
(i.e., the current state of the patient is either in state 3
or state 4, depending on the initial NNRTI component)
who has had no further events at one year post ART, one
may be interested in estimating the probability of staying
on this combination for additional 6 months as well as in
comparing this probability to a patient who did not sub-
stitute their NRTI (d4T). We propose to use the transition
probabilities for long-term prediction of a patient’s state.
Let s be the time at which the prediction ismademeasured
from the time origin of the patient (start of treatment)
and let us denote the event history of the patient up to
time s by Xu, 0 ≤ u ≤ s. Then, the transition probabil-
ity from state  to state j in the time interval [ s, t], given
information available until time s, is defined as
Pj(s, t) = P(Xt = j | Xs = ,Xu), s ≤ t, , j ∈ {1, 2, ..., 6},u ∈ [ 0, s].
(2)
In order to estimate Pj(s, t) we proposed to use a
Markov model [28]. The model assumes that the future
course of the patient depends on the patient’s state in
the current time but not on the patient’s history before
the current state. This means that, conditional on the
present state, the past has no influence on the risk. This
implies that
aj(t)dt = P(X(t+t)− = j|Xt− = ), , j ∈ {1, 2, ..., 6},  = j (3)
and
Pj(s, t) = P(Xt = j | Xs = ), s ≤ t, , j ∈ {1, 2, ..., 6}. (4)
Analogous toA(t),these probabilities can be gathered in
to a 6 × 6 matrixM(s, t) with (Pj(s, t)) as its (, j)th entry.
A single element (Pj(s, t)) combines both direct and indi-
rect transition from state  to state j. The matrix is fully
presented in Additional file 1: Section S.2.
Inference
In this section we present non-parametric approaches
for time continuous Markov models with finite state
space and under independent right censoring. We con-
sider n individual multistate processes
(
X(i)t
)
t≥0 ,X
(i)
t ∈
{1, ..., 6}, and i = 1, 2, ..., n. We assume that the n process
are all, conditional on the initial state X(i)0 , independent
multistate processes. Observation of the individual mul-
tistate data is subject to a right censoring time Ci. Our
notation and ideas are based on a counting process formu-
lation [29, 30].
Let Nj;i(t) be the counting process denoting individual
i′s number of observed direct (without visiting another
state in between)  → j transition in [ 0, t] , , j ∈
1, 2, . . . , 6,  = j. Here, time t refers to the time since
the patient entered the initial state (i.e., the time since
ART initiation). Let Y;i(t) be an indicator variable which
represent the at risk process where we have
Y;i(t) =
⎧
⎨
⎩
1 : if individual i is in state  and under observation before time t,
0 : otherwise.
Let the aggregated process Nj(t) = ∑ni=1Nj;i(t),  = j
and Y(t) = ∑ni=1 Y;i(t) denote, respectively, the number
of observed direct  → j transitions during the time inter-
val [ 0, t] and the number of individuals to be observed
at risk in state  just prior to time t. We define the the
increment of Nj(t) as Nj(t) = Nj(t) − Nj(t−) for the
increment of Nj(t) which gives the number of  → j
transitions observed exactly at time t.
Nonparametric estimation of baseline hazards
From the definition of the transition intensities in Eq. (3)
ajdt = P(X(t+dt)− = j | Xt− = ),  = j. Hence, if we
observe no  → j transition at t (i.e Nj(t) = 0) we esti-
mate the increment aj(t)dt of the cumulative hazard as 0.
If we do observe  → j transition at t (i.e Nj(t) > 0) ,
we estimate this conditional transition probability by
Aˆj(t) = Nj(t)Y(t) , (5)
summing up over these increments yields the Nelson-
Aalen estimators [29]
Aˆj(t) =
∑
s≤t
Nj(s)
Y(s)
,  = j, (6)
where summation is over all observed event times in [ 0, t]
and its variance is given by
δˆ2j(t) =
∑
s≤t
Nj(s)
Y 2 (s)
,  = j. (7)
Nonparametric estimation of Transition probabilities
The transition probabilities are a complex function of the
transition hazards, because the state occupied at some
time t may potentially result from a complex nested
series of competing risks experiments and there may also
be more than one possible sequence of competing risks
experiments leading to being in a certain state at a certain
time [31]. Under the Markov model the transition proba-
bilities defined in (4) are the solution of a set of differential
equations [29]
d
dtM(s, t) = A
T (t)M(s, t), (8)
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where M(s, t) is transition probability matrix with (, j)
element Pj(s, t) = P(Xt = j | Xs = ) and A(t) is a matrix
with off diagonal elements Aj(t) = a(t) and diagonal
elements A(t) = −∑6j=1,j = aj(t). In coordinates, (8)
is d/dtPj(s, t) = ∑k Pk(s, t)Akj(t) and for any fixed ini-
tial state , the vector of transition probabilities from ,
(P1(s, t),P2(s, t), ...,P6(s, t)) satisfies this equation. Even
though this equation can not be solved in general due to
the non-constancy over time of the matrix A(t), under
Markov assumption, the transition probabilities satisfy
Pj(s, t) =
∑
r
Pr(s,u)Prj(u, t) , s ≤ u ≤ t, (9)
and based on a partition s = t0 < t1 < t2 < . . . < tk−1 <
tk = t of the time interval [ s, t], the matrix of transition
probabilitiesM(s, t) can be approximated by [31]
M(s, t) ≈
K∏
k=1
(I + A(tk)), (10)
where I is the (6 × 6) identity matrix, the (, j)th element
of A(tk) is equal to Aj(tk) − Aj(tk−1), and A(t) =
−∑6j=1,j =l Alj(t). Computing the approximation for ever
finer partition [ s, t] approaches a limit, namely a matrix-
valued product integral [31, 32], which equals the matrix
of transition probabilities,
M(s, t) =
∏
u∈(s,t]
(I + dA(u)), (11)
where u ranges from s to t and dA(u) is defined as
dAj(u) = aj(u)du, , j ∈ 1, 2, ..., 6 [29]. Therefore, for
Markov models, given A(t), the product integration is the
mapping that switches from cumulative transition haz-
ards to the matrix of transition probabilities while all
cumulative transition hazards are involved.
An estimator of M(s, t) can be obtained by replac-
ing A(u) with the Nelson-Aalen estimators, Aˆ(u), and
by defining dAˆ(u) as the matrix with entries Aˆ(u) =
Aˆj(u) − Aˆj(u−) (i.e., the increment of the Nelson-Aalen
estimators at time u). This results in the Aalen-Johansen
type estimator [29],
Mˆ(s, t) =
∏
u∈(s,t]
(I + Aˆ(u)), (12)
in which u indicates all event times in (s, t]. Note that
the transition probability matrix defined in (11) is calcu-
lated by means of a product integral, while its estimator
in (12) is based on a finite product, which only changes at
event times.
The transition probabilities can be used for two types
of prediction: forward and fixed horizon [30, 33]. In the
former case, at a given fixed time s the probabilities of pos-
sible future events are evaluated for varying time horizons
t. In the latter case, the prediction is made from several
starting points to one future fixed time point. In both
cases, Aalen-type or Greenwood type estimators of the
variance-covariance matrix of M(s, t) can be calculated
directly or through a recursion formula which can for
instance be used to construct point-wise confidence inter-
vals around the estimated transition probability curves
[30]. In our application we use forward prediction type.
Robustness of First-line HAART towards Treatment
Modification/change
The primary aim of this study is to quantify the robustness
of first line treatments to treatment modification. Given
the individuals initial state  at time s, the waiting time in
state . i.e., the duration of stay at state , can be used as a
summary measure of the model. The waiting time in state
 is generated with hazard
a.(t) =
6∑
j=1,j =
aj(t), t >= 0.
We define the total cumulative transition hazard out of
state  as A.(t) =
∫ t
0 a.(u)du =
∑6
j=1,j = Aj(t). Using
these quantities one can evaluate the probability of no
events during a period. The survival function of the wait-
ing time in the initial state , i.e., probability to stay in state
 until time t, given that the individual had already been in
the respective state at time s, s ≤ t is given by,
P(Xt = |xs = ) =
∏
u∈(s,t]
(1 − a.(u)du)
= exp
(
−
∫ t
s
a.(u)du
)
= exp(−A.(t)) = 1, ..., 6.
These quantities are essentially common survival prob-
abilities with all cause hazard a.(u), taking time s as time
origin [31]. However, this can also be seen as a solu-
tion of the product integral in (11). Since, the th row
of the Aalen-Johansen type estimator of Mˆ(s, t) contains
the estimates Pˆj(s, t) for  = j and the diagonal ele-
ment is such that the sum over the th row equals 1, the
Aalen-Johansen estimator of P(Xt = |xs = ) is just
Pˆ(s, t).
The multi-state model formulated above allows us to
evaluate whether treatment modification reflect a substi-
tution of NNRTI, substitution of NRTI or substitution of
both NNRTI and NRTI by initial treatment combinations.
We propose to use the following measures of HAART
robustness to treatment modification:
1. Probability of NNRTI substitution
P12 for state 1 P34 for state 3 P56 for state 5
P21 for state 2 P43 for state 4 P65 for state 6
2. Probability of NRTI substitution
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P13 + P16 for state 1 P35 + P36 for state 3 P54 + P52
for state 5
P24 + P25 for state 2 P42 + P45 for state 4 P63 + P61
for state 6
3. Probability of regimen switching
P14 + P15 for state 1 P32 + P35 for state 3 P53 + P51
for state 5
P23 + P26 for state 2 P41 + P46 for state 4 P64 + P62
for state 6
Result
Of the 1453 eligible patients, 169 patients were excluded
because of limited follow up (i.e those with at most 1
month follow-up data) and missing information (patients
with missing information about prescribed ARV or start
and stop dates of the drug). A total of 1284 subjects were
included for the analysis presented in this paper. Patients
person-time were cut at the earliest of changing to sec-
ond line treatment, death, lost to followup, transfer or end
of study (Aug 25, 2013). The median follow-up time was
37.40 months (IQR: 22.32-56.15 months) and the average
follow-up time was 38.25 months per person.
At ART initiation, patients had a median CD4 cell count
of 137cells/mm3 (IQR: 78-201 cells/mm3), were predom-
inately female (68.81%) and had a median age of 30 years
(IQR: 26-35 years) (Table 1). The most common regimens
initiated were d4T + 3TC + EFV consisting of 526(40.96%)
Table 1 Baseline characteristics of study subjects
Characteristics n(%)
Gender (n(%)) Male 439(34.19)
Female 845(68.81)
WHO Stage(n(%)) SI 372(28.97)
SII 398(30.99)
SIII 419(32.63)
SIV 95(7.41)
Treatment at start(n(%)) 1 526(40.96)
2 67(5.22)
3 185(14.41)
4 82 (6.39)
5 401(31.23)
6 23(1.79)
Age (Median (IQR)) 30 (26-35)
Baseline CD4 (Median (IQR)) 137(78-201)
Status at the end(n(%)) Dead 52(4.05)
Drop 197(15.34)
Transfer 127(9.89)
Under follow up 908(70.72)
Note: 1: d4T + 3TC + NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC
+ EFV, 5: TDF + 3TC + EFV, and 6: TDF + 3TC + NVP
patients while the treatment TDF + 3TC + EFV was
administered to 401(31.23%) patients at initiation.
For the majority of the patients (58.8%) the first line
treatment was not modified, 442 patients (34.4%) had
their treatment changed only once while 86 patients
(6.69%) had their treatment changed more than once.
In total, 615 (32.4%) treatment changes occurred in this
cohort over the period of follow-up. Of those 615 changes,
426 (69.27%) substituted NRTI only, 144 (23.41%) substi-
tuted NNRTI only and 45 (7.32%) substituted both the
NRTI and NNRTI at the same time. The number of events
(transition made from each state) and the number of
patients in total that were at risk for treatment modifi-
cation are presented in Table 2. Five hundred forty one
patients were on d4T + 3TC +NVP combination, but only
125 (23%) remained on this regimen without any modifi-
cation. 89% of the 483 patients who were on AZT + 3TC
+ NVP and 95% of the 89 patients who were on TDF +
3TC + NVP did not experience treatment modification.
Among the regimens containing EFV, 36% of 157 patients
on d4T + 3TC + EFV, 86% of 161 patients on AZT + 3TC
+ EFV and 96% of 471 patients on TDF + 3TC + EFV did
not experience treatment modification. The frequency of
treatment change was the lowest amongst those patients
initiated on TDF-based regimens (3.75%) compared to
those initiated on AZT (11.96%) and d4T-based regimens
(73.92%). It is interesting that regimens containing d4T
were more prone to treatment modification than those
containing AZT and TDF. Apart from d4T, patients who
received NVP (42.5%) were more susceptible to treatment
modification than patients who received EFV (17.87%).
As seen from Fig. 2 (Panel b), however, when we
look at the time spent in the current treatment com-
bination of the patients who modified their treat-
ment, patients initiated on d4T had a tendency to
stay longer (40.40 months; IQR: 14.60-55.73) as com-
pared to AZT patients (3.7 months; IQR: 1.90-16.02)
and TDF patients (12.60 months; IQR: 6.84-20.40). Sim-
ilarly, patients initiated on NVP had a tendency to
stay longer (38.37 months; IQR: 5.42-56.05) as com-
pared to EFV patients (21.80 months; IQR: 8.70-39.80)
(Fig. 2 (Panel c)) . The duration of stay in each treatment
combination before the first change to another treatment
combination is presented in Additional file 1: Figure S3.1.
The multistate model described in the previous section
was estimated using the mstate packagee developed by
[34]. Details about different R function used for the esti-
mation is given in Additional file 1: Section S1. In particu-
lar, using the estimated transition hazards as described in
Eq. (12), we calculate the transition probabilities Pj(s, t)
from all starting states to all possible states, between the
starting time s = 0 and all event times successively. Note
that several probabilities estimates cannot be obtained
due to limited information in some states. As shown in
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Table 2 Observed transition matrix
1 2 3 4 5 6 No event Total entering
1 - 87(0.16) 271(0.50) 2(0.004) 15(0.028) 41(0.08) 125(0.23) 541
2 5(0.03) - 12(0.08) 48(0.31) 34( 0.22) 1(0.006) 57(0.36) 157
3 7(0.014) 0(0.00) - 25(0.052) 10(0.021) 11( 0.023) 430(0.89) 483
4 1(0.006) 1(0.006) 12( 0.075) - 10(0.063) 0(0.000) 137(0.85) 161
5 0(0.000) 1(0.002) 2(0.004) 1(0.002) - 13(0.027) 454(0.96) 471
6 0(0.000) 0(0.000) 1(0.011) 1(0.011) 2(0.022) - 85(0.95) 89
Note: 1: d4T + 3TC + NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, and 6: TDF + 3TC + NVP. The jth entries are the frequencies
(percentage) of transition from state  to state j. Those in column "no event" are the numbers of patients ending the study in each state and those in column "total entering"
are the numbers of patients observed to be in each state at some time point prior to the end of the study
Table 2, treatment change was observed only in 4 out of
the 89 patients initiated on TDF + 3TC + NVP; hence
we have chosen to consider as inadmissible the occur-
rence treatment modification from this treatment com-
bination (State 6). The model has 6-states as before but
with a different transition matrix. The transition matrix in
Additional file 1: Section S1 shows themultistate structure
which reflects this framework. We show in Fig. 3 the esti-
mated transition probabilities from all starting states to
all possible states, between the starting time s = 0 and
all event times successively. Treatment combinations con-
taining d4T have the lowest probability of no treatment
modification while the combination of TDF and EFV are
the most robust to treatment modification.
a
b
c
Fig. 2 Duration on treatment before switch in months. a Duration in original treatment combination before switch, b Duration in original NRTI
before switch, and c Duration in original NNRTI before switch. Note that only the time spent in the current treatment combination of the patients
who modified their treatment are considered
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Fig. 3 Transition probability starting from each state. Note: the estimate contain both direct and indirect transition probabilities. 1: d4T-3TC-NVP, 2:
d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, 6: TDF + 3TC + NVP
As mentioned above, we are mainly interested in pre-
diction of the four measures of HAART robustness to
treatment modification: (1), probability of no treatment
modification, (2) NRTI substitution, (3) NNRTI substitu-
tion and (4) regimen changes. The estimated probabilities
are shown in Fig. 4. As was to be expected on the basis of
the previous discussion, the prospects for a patient who
received the regimens containing d4T are indeed worse
than those patient who received the regimens containing
AZT or TDF, the former having a far larger probabil-
ity of NRTI substitution, regimen changes and the lowest
treatment modification-free survival probabilities.
As mentioned above, treatment modification occurs
more frequently for AZT and TDF early after treatment
initiation while it occurs later on in follow-up among
patients on d4T. Thus, it is interesting to compare treat-
ments based on the situation after some months to
account for early ART complication. For this, the tran-
sition probabilities at 10 months post ART were esti-
mated and the results are presented in Fig. 5. A compar-
ison of Figs. 4 and 5 clearly shows that the fact that a
patient on a treatment combination containing AZT or
TDF has not had any early ART complication leading to
treatment change or modification in the first 10 months
post-ART has decreased his/her probability of future
treatment change or modification considerably; notably,
his/her probability of long-term NRTI substitution-free
survival has increased significantly. On the other hand,
the long-term treatment modification-free survival of
a patient on a treatment combination containing d4T
was unchanged by the fact that he/she has not expe-
rienced treatment modification in the first 10 months
post-ART.
Reason for treatment modification
Table 3 shows the reason for treatment change for the
total 615 observed treatment changes in the cohort, strat-
ified by treatment combinations. We were able to obtain
the reason for the majority of treatment changes (88.62%).
Toxicity and comorbidity were was the main reasons for
treatment modification accounting for 48.94% and 14.31%
of the observed treatment changes, respectively. About
50% of the patients on all the regimens except TDF +
3TC + EFV reported toxicity or side effects. In addition,
phasing out of d4T from the NRTI backbone accounts for
20.16% of the observed treatment changes.
In order to quantify the effect of toxicity on treatment
change, we modify the definition of time-to-treatment
change to time-to-treatment change due to toxicity. Here,
treatment change related to other reasons during the
follow-up period were censored at the time of their occur-
rence. As seen from Table 4, a large proportion of patients
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a
c
b
d
Fig. 4 Prediction probabilities at s = 0 for a reference patient. a Probability of no treatment modification, b Probability of NRTI substitution,
c Probability of NNRTI substitution and d Probability of regimen changes. 1: d4T-3TC-NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC +
EFV, 5: TDF + 3TC + EFV, 6: TDF + 3TC + NVP
a
c
b
d
Fig. 5 Prediction probabilities at s = 10 for a reference patient. a Probability of no treatment modification, b Probability of NRTI substitution,
c Probability of NNRTI substitution and d Probability of regimen changes. 1: d4T-3TC-NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC +
EFV, 5: TDF + 3TC + EFV, 6: TDF + 3TC + NVP
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Table 3 Reasons for antiretroviral modification among HIV patients on HAART
1 2 3 4 5 6 Total
Drug out of stock 0(0.00) 0(0.00) 3(5.56) 0 (0.00) 0 (0.00) 0(0.00) 3(0.48)
Hepatitis 0(0.00) 0(0.00) 1 (1.85) 0 (0.00) 0(0.00) 0(0.00) 1(0.16)
New TB 68(16.35) 3(3.00) 15 (27.78) 0 (0.00) 1(5.88) 1(25.00) 88(14.31)
Phaseout 106(25.48) 18 (18.00) 0(0.00) 0 (0.00) 0(0.00) 0(0.00) 124(20.16)
Pregnancy 1(2.40) 6 (6.00) 0 (0.00) 5 (20.83) 11(64.70) 1(25.00) 24(3.9)
Toxicity/side effect 198(47.59) 56(56.00) 29 (53.70) 13 (54.17) 3(17.65) 2(50.00) 301(48.94)
Treatment failure 2(4.1) 1 (1.00) 1 (1.85) 0 (0.00) 0 (0.00) 0(0.00) 4(0.65)
unknown 41 (9.86) 16 (16.00) 5 (9.26) 6 (25.00) 2 (11.76) 0(0.00) 70(11.38)
Total change 416 100 54 24 17 4 615
Note: 1: d4T + 3TC + NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, and 6: TDF + 3TC + NVP
(26.25%) on NVP and d4T combination had NRTI substi-
tution with d4T replaced by AZT due to toxicity. Similarly,
15.92% and 14.01% of patients on EFV combination with
d4T had d4T replaced by AZT and TDF, respectively due
to toxicity. Treatment combination of TDF and EFV was
the most robust to treatment modification among the six
first line regimens. As previously noted, this combination
seems the least toxic.
In a similar fashion, we calculate the toxicity driven
transition probabilities Pj(s, t) from all starting states to
all possible states, between the starting time s = 0 and
all event times successively and extract the four measures
of transition probabilities. Here again, Fig. 6 shows treat-
ment combination containing d4T had highest probability
for treatment modification due to toxicity. Where as the
combination of TDF and EFV was the most robust to
treatment modification.
Discussion
This study has provided unique and important data on
durability of first-line ART and on reasons responsible
for antiretroviral treatment modification in the setting
of a tertiary care Hospital in a resource limited coun-
try. This work adds to the previous observational studies
[15–18, 22–27] conducted in resource-limited settings,
where no distinction was made between NRTI substitu-
tion and NNRTI substitution, treatment modification due
to all causes and toxicity driven treatment modification,
and the incidence of subsequent treatment modification
was not studied. Further, we show how a simple multi-
state survival model can be used to estimate the proba-
bility of the future treatment combination of the patient
given all the information available up to the present
moment.
In our cohort, a large proportion of patients (41.2%)
changed their treatment during follow up time, where
34.4% patients changed once and 6.69% changed more
than once, which is far higher to what has been previously
reported [22, 27]. The short follow up time and consider-
ation of only the first treatment modification as event of
interest in their study may be the reason for such discrep-
ancy. Among the regimens containing d4T, 77% of 541
patients on d4T + 3TC + NVP and 64% of 157 patients
on d4T + 3TC + EFV experienced all cause treatment
modification. In all cause analysis, regimens containing
d4T had highest probability for treatment modification,
NRTI substitution, and regimen switching as compared to
those regimens containing AZT and TDF, consistent with
previous findings [15–18, 22–27]. Whereas the combina-
tion of TDF and EFV was the most robust to treatment
Table 4 Observed transition matrix
1 2 3 4 5 6 No event Total entering
1 - 15(2.77) 142(26.25) 2(0.36) 6(1.10) 33(6.09) 343(63.40) 541
2 2(1.27) - 5 (3.18) 25 (15.92) 22(14.01) 1(0.63) 102(64.96) 157
3 7(1.44) 0(0.00) - 6(1.24) 7(1.45) 9(1.85) 455(94.00) 483
4 0(0.00) 1(0.60) 5 (3.05) - 7(4.26) 0(0.00) 151(92.07) 161
5 0(0.00) 1(0.21) 0 (0.00) 0(0.00) - 2(0.42) 470(99.36) 471
6 0(0.00) 0(0.00) 1 (1.12) 1(1.12) 0(0.00) - 87(97.75) 89
Note: 1: d4T + 3TC + NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, and 6: TDF + 3TC + NVP. The jth entries are the frequencies
(percentage) of toxicity driven transition from state  to state j. Those in column "no event" are the numbers of patients ending the study in each state and those in column
"total entering" are the numbers of patients observed to be in each state at some time point prior to the end of the study
Birlie et al. BMC Infectious Diseases  (2017) 17:453 Page 11 of 13
a
c
b
d
Fig. 6 Prediction probabilities for time to treatment change due to toxicity at s = 0 for a reference patient: a Probability of no treatment
modification, b Probability of NRTI substitution, c Probability of NNRTI substitution and d Probability of regimen changes. 1: d4T-3TC-NVP, 2: d4T +
3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, 6: TDF + 3TC + NVP
modification. Apart from d4T, patients on EFV were less
susceptible to treatment modification than patients on
NVP, similar to what has been reported previously [27].
We also found that treatment modification occurring
more frequently for AZT and TDF early after treatment
initiation while treatment modification occurs later on in
follow-up amongst patients on d4T, consistent with pre-
vious findings [27]. The superiority of AZT and TDF over
d4T, however, should not be shadowed by this finding. A
further comparison of treatment combinations account-
ing for early ART complication shows that, if a patient on
a treatment combination containing AZT or TDF has not
had any early ART complication leading to modification
in the first 10 months post-ART his probability of future
treatment modification decreased considerably. On the
other hand, the long-term treatment modification-free
survival of a patient on a treatment combination contain-
ing d4T was unchanged by the fact that he/she has not
experienced treatment modification in the first 10 months
post-ART. Further, no significant difference in the tim-
ing of treatment modification was observed among NVP
and EFV.
The unique feature of this study is we manage to
determine the type of treatment modification along with
the reason for modification. Only in less than 7% of
the treatment changes were we unable to determine
the reason for treatment modification. Toxicity-related
treatment modification has been identified as the most
common reason for treatment modification accounting
for 48.94% of the changes, followed by comorbidity (New
TB) 14.31%, similar to what has been reported previously
[15–18, 22–27]. About 50% of the patients on all the
regimens except TDF plus EFV reported toxicity or side
effects. The largest number of treatment modification due
to toxicity was in patients on d4T: approximately 27% of
those who originally started with NVP and d4T combina-
tion hadNRTI substitution with d4T replaced by AZT and
15.92% and 14.01% patients who originally started with
EFV combination with d4T had d4T replaced by AZT
and TDF,respectively. Treatment combination of TDF and
EFV was the most robust to toxicity related treatment
modification among the six first line regimens. As pre-
viously noted, this combination seems the least toxic.
This is a significant finding because TDF is a WHO rec-
ommended preferred treatment, with AZT as alternative
[20]. Phasing out of d4T also accounted for 20.16% of
treatment changes observed in our study.
This study provided unique and important data on dura-
bility of first-line ART and on reasons responsible for
antiretroviral treatment modification in a resource lim-
ited setting. Furthermore, the study shows the use of
multi-state models to study the evolution of patient’s state
(treatment regimen) over time and to predict the proba-
bility of changing treatment. The proposed model allow
us to model both the occurrence of different event types
(such as, single drug substitution or regimen switch ) and
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the occurrence of subsequent events, the latter potentially
of different types in a unified way.
Our findings must be interpreted in light of some lim-
itations. Our model assumes that the future course of a
patient only depends on where you are at the current time,
but not on how you got there. Deviations from this could
have led to bias.
Conclusion
Our study shows the burden of toxicity/side effect related
to d4T use is a matter of major concern, as it accounts
for the majority of modifications. Safer andmore tolerable
regimens like a combination of TDF and EFV should be
made more accessible to treatment programs in resource-
limited settings. Moving away from drugs with poor safety
profiles, such as d4T, could reduce modification rates and
this would improve regimen tolerability, while preserving
future treatment options.
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